These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

136 related items for PubMed ID: 8695369

  • 21.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 22.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 23.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 24. Folate-based thymidylate synthase inhibitors in cancer chemotherapy.
    Takemura Y, Jackman AL.
    Anticancer Drugs; 1997 Jan; 8(1):3-16. PubMed ID: 9147608
    [Abstract] [Full Text] [Related]

  • 25. Open, randomized, multicenter trial of raltitrexed versus fluorouracil plus high-dose leucovorin in patients with advanced colorectal cancer. Tomudex Colorectal Cancer Study Group.
    Cocconi G, Cunningham D, Van Cutsem E, Francois E, Gustavsson B, van Hazel G, Kerr D, Possinger K, Hietschold SM.
    J Clin Oncol; 1998 Sep; 16(9):2943-52. PubMed ID: 9738562
    [Abstract] [Full Text] [Related]

  • 26. Patterns of elevation of plasma 2'-deoxyuridine, a surrogate marker of thymidylate synthase (TS) inhibition, after administration of two different schedules of 5-fluorouracil and the specific TS inhibitors raltitrexed (Tomudex) and ZD9331.
    Ford HE, Mitchell F, Cunningham D, Farrugia DC, Hill ME, Rees C, Calvert AH, Judson IR, Jackman AL.
    Clin Cancer Res; 2002 Jan; 8(1):103-9. PubMed ID: 11801545
    [Abstract] [Full Text] [Related]

  • 27. Clinical trials referral resource. Clinical trials with tomudex.
    Sorensen JM, Cheson BD, Phillips PH.
    Oncology (Williston Park); 1996 Jul; 10(7):1041-2. PubMed ID: 8837120
    [No Abstract] [Full Text] [Related]

  • 28. Thymidylate synthase inhibitors in cancer therapy: direct and indirect inhibitors.
    Rustum YM, Harstrick A, Cao S, Vanhoefer U, Yin MB, Wilke H, Seeber S.
    J Clin Oncol; 1997 Jan; 15(1):389-400. PubMed ID: 8996166
    [Abstract] [Full Text] [Related]

  • 29. A Phase I study of raltitrexed, an antifolate thymidylate synthase inhibitor, in adult patients with advanced solid tumors.
    Grem JL, Sorensen JM, Cullen E, Takimoto CH, Steinberg SM, Chen AP, Hamilton JM, Arbuck SG, McAtee N, Lawrence D, Goldspiel B, Johnston PG, Allegra CJ.
    Clin Cancer Res; 1999 Sep; 5(9):2381-91. PubMed ID: 10499608
    [Abstract] [Full Text] [Related]

  • 30. Thymidylate synthase inhibitors.
    Touroutoglou N, Pazdur R.
    Clin Cancer Res; 1996 Feb; 2(2):227-43. PubMed ID: 9816165
    [Abstract] [Full Text] [Related]

  • 31. Efficacy and tolerability of a new inhibitor of thymidylate synthase: 'Tomudex' (raltitrexed).
    Cunningham D.
    Tumori; 1997 Feb; 83(1 Suppl):S70-1. PubMed ID: 9154074
    [No Abstract] [Full Text] [Related]

  • 32. The use of raltitrexed (tomudex) in a patient with 5-fluorouracil induced myocardial ischaemia.
    Nutting C, Folkes A.
    Clin Oncol (R Coll Radiol); 1999 Feb; 11(1):66. PubMed ID: 10194593
    [No Abstract] [Full Text] [Related]

  • 33. A phase II trial of raltitrexed (Tomudex) in advanced pancreatic and biliary carcinoma.
    François E, Hebbar M, Bennouna J, Mayeur D, Perrier H, Dorval E, Martin C, Bourgeois H, Barthélemy P, Douillard JY.
    Oncology; 2005 Feb; 68(4-6):299-305. PubMed ID: 16020956
    [Abstract] [Full Text] [Related]

  • 34. Preoperative chemoradiation with raltitrexed ('Tomudex') for T2/N+ and T3/N+ rectal cancers: a phase I study.
    Valentini V, Doglietto GB, Morganti AG, Turriziani A, Smaniotto D, De Santis M, Ratto C, Sofo L, Cellini N.
    Eur J Cancer; 2001 Nov; 37(16):2050-5. PubMed ID: 11597383
    [Abstract] [Full Text] [Related]

  • 35. Comparison of plasma and tissue levels of ZD1694 (Tomudex), a highly polyglutamatable quinazoline thymidylate synthase inhibitor, in preclinical models.
    Aherne GW, Ward E, Lawrence N, Dobinson D, Clarke SJ, Musgrove H, Sutcliffe F, Stephens T, Jackman AL.
    Br J Cancer; 1998 Nov; 77(2):221-6. PubMed ID: 9460992
    [Abstract] [Full Text] [Related]

  • 36. Antitumor activity of ZD1694 (tomudex) against human head and neck cancer in nude mouse models: role of dosing schedule and plasma thymidine.
    Cao S, McGuire JJ, Rustum YM.
    Clin Cancer Res; 1999 Jul; 5(7):1925-34. PubMed ID: 10430100
    [Abstract] [Full Text] [Related]

  • 37. Tolerability of Raltitrexed ('Tomudex') in elderly patients with colorectal cancer.
    Romiti A, Tonini G, Santini D, Di Seri M, Masciangelo R, Mezi S, Verì A, Santuari L, Vincenzi B, Brescia A, Marchei P, Frati L, Tomao S.
    Anticancer Res; 2002 Jul; 22(5):3071-6. PubMed ID: 12530045
    [Abstract] [Full Text] [Related]

  • 38. Raltitrexed (Tomudex): an alternative choice in patients intolerant to 5-fluorouracil.
    Kempin S, Gutierrez J, Wilson E, Lowery C, Diasio R.
    Cancer Invest; 2002 Jul; 20(7-8):992-5. PubMed ID: 12449732
    [Abstract] [Full Text] [Related]

  • 39. [Raltitrexed in colorectal cancer].
    Comandone A, Oliva C, Dal Canton O, Boglione A, Bergnolo P.
    Tumori; 2001 Jul; 87(1 Suppl 1):S53-4. PubMed ID: 11300026
    [No Abstract] [Full Text] [Related]

  • 40. The potential role of Tomudex in the treatment of advanced colorectal cancer.
    Sobrero AF.
    Tumori; 1997 Jul; 83(2):576-80. PubMed ID: 9226024
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 7.